Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
Sagar Sardesai(The Ohio State University), Bhuvaneswari Ramaswamy(The Ohio State University), Robert Wesolowski(The Ohio State University Wexner Medical Center), Daniel G. Stover(Harvard University), Jeffrey VanDeusen(The Ohio State University), Ragavendra R. Baliga, Daniel Addison(The University of Texas Southwestern Medical Center), Julie Stephens(The Ohio State University), Evan Morgan(The Ohio State University), Mathew Cherian(The Ohio State University Wexner Medical Center), Marilly Palettas(The Ohio State University Wexner Medical Center), Maryam B. Lustberg(Yale Cancer Center), Mahmoud Kassem(The Ohio State University), Nicole Williams(The Ohio State University), Jasmine Sukumar(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 32
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet|2022|955
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
|Nature|2016|629
Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells
|Proceedings of the National Academy of Sciences|2017|373